Colin Miles

440 total citations
8 papers, 321 citations indexed

About

Colin Miles is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Colin Miles has authored 8 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 1 paper in Genetics. Recurrent topics in Colin Miles's work include TGF-β signaling in diseases (6 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Colin Miles is often cited by papers focused on TGF-β signaling in diseases (6 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Colin Miles collaborates with scholars based in United States, United Kingdom and Spain. Colin Miles's co-authors include Ivelina Gueorguieva, Ann Cleverly, Jordi Rodón, Michael Lahn, David Capper, Joachim P. Steinbach, Alba A. Brandes, Claire Smith, Juan Manuel Sepúlveda-Sánchez and Helen Wheeler and has published in prestigious journals such as British Journal of Pharmacology, Molecular Cancer Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

Colin Miles

8 papers receiving 317 citations

Peers

Colin Miles

ONCOL

MB

GENET

IMMUN

CR

Kevin T. Kane United States

K. Jin Kim United States

Carson Stephens Australia

Jessie-F. Fecteau United States

Gustavo Roversi United States

Sarah Gaffey United States

Chery A. Whipple United States

Yin-sheng Chen China

Joseph W. Po Australia

Chih‐Ming Pan Taiwan

Kevin T. Kane United States

Colin Miles

210 ×1.2

ONCOL

174 ×1.1

MB

48 ×0.5

GENET

71 ×1.2

IMMUN

77 ×1.3

CR

Citations per year, relative to Colin Miles Colin Miles (= 1×) peers Kevin T. Kane

Countries citing papers authored by Colin Miles

Since Specialization

Citations

This map shows the geographic impact of Colin Miles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Miles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Miles more than expected).

Fields of papers citing papers by Colin Miles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Miles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Miles. The network helps show where Colin Miles may publish in the future.

Co-authorship network of co-authors of Colin Miles

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Miles. A scholar is included among the top collaborators of Colin Miles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Miles. Colin Miles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Gueorguieva, Ivelina, Josep Tabernero, Davide Melisi, et al.. (2019). Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology. 84(5). 1003–1015. 18 indexed citations

2.

Cassidy, Kenneth C., Ivelina Gueorguieva, Colin Miles, et al.. (2017). Disposition and metabolism of [ ¹⁴ C]-galunisertib, a TGF- β RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. Xenobiotica. 48(4). 382–399. 8 indexed citations

3.

Gueorguieva, Ivelina, Ann Cleverly, D. Desaiah, et al.. (2016). Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. Drugs in Context. 5. 1–8. 1 indexed citations

4.

Brandes, Alba A., Alain Carpentier, Santosh Kesari, et al.. (2016). A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology. 18(8). 1146–1156. 204 indexed citations

5.

Gueorguieva, Ivelina, Ann Cleverly, Anja J. Stauber, et al.. (2013). Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. British Journal of Clinical Pharmacology. 77(5). 796–807. 66 indexed citations

6.

Raymond, Éric, Sandrine Faivre, Robin Kate Kelley, et al.. (2013). Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients.. Molecular Cancer Therapeutics. 12(11_Supplement). C261–C261. 2 indexed citations

7.

Wang, Yun, et al.. (2006). TC‐2559 excites dopaminergic neurones in the ventral tegmental area by stimulatingα4β2‐like nicotinic acetylcholine receptors in anaesthetised rats. British Journal of Pharmacology. 147(4). 379–390. 21 indexed citations

8.

Hoffman, William D., et al.. (1998). Abnormal spinal fluid in hypertensive encephalopathy.. PubMed. 51(3). 77–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact